Trimipramine
Trimipramine (trimipramine) is a small molecule pharmaceutical. Trimipramine was first approved as Surmontil on 1982-01-01. It is used to treat depressive disorder and psychotic affective disorders in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter, sodium-dependent dopamine transporter, and sodium-dependent noradrenaline transporter. In addition, it is known to target G protein-activated inward rectifier potassium channel 2, muscarinic acetylcholine receptor M2, voltage-gated delayed rectifier potassium channel KCNH1; potassium voltage-gated channel subfamily H member 1, and G protein-activated inward rectifier potassium channel 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Trimipramine (discontinued: Surmontil)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| trimipramine maleate | ANDA | 2025-07-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psychotic affective disorders | — | D000341 | F39 |
| depressive disorder | EFO_1002014 | D003866 | F32.A |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | 1 | 2 | — | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 2 | — | 2 |
| Atrophy | D001284 | — | — | — | — | — | 1 | — | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 1 | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trimipramine |
| INN | trimipramine |
| Description | Trimipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant. It has a role as an antidepressant, an environmental contaminant and a xenobiotic. It is a dibenzoazepine and a tertiary amino compound. It is functionally related to an imipramine. |
| Classification | Small molecule |
| Drug class | antidepressants (imipramine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(CN(C)C)CN1c2ccccc2CCc2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 739-71-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL644 |
| ChEBI ID | 9738 |
| PubChem CID | 5584 |
| DrugBank | DB00726 |
| UNII ID | 6S082C9NDT (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNH1
KCNH1
Organism
Homo sapiens
Gene name
KCNH1
Gene synonyms
EAG, EAG1
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily H member 1
Protein synonyms
EAG channel 1, ether-a-go-go 1, Ether-a-go-go potassium channel 1, ether-a-go-go, Drosophila, homolog of, h-eag, hEAG1, potassium channel, voltage gated eag related subfamily H, member 1, potassium voltage-gated channel, subfamily H (eag-related), member 1, Voltage-gated potassium channel subunit Kv10.1
Uniprot ID
Mouse ortholog
Kcnh1 (16510)
potassium voltage-gated channel subfamily H member 1 (Q60603)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Trimipramine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,743 documents
View more details
Safety
Black-box Warning
Black-box warning for: Trimipramine maleate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,094 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use